Persistent URL of this record https://hdl.handle.net/1887/114002
In Collections
This item can be found in the following collections:
Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial
- All authors
- Bayani, J.; Yao, C.Q.; Quintayo, M.A.; Haider, S.; Brookes, C.L.; Yan, F.; Velde, C.J.H. van de; Hasenburg, A.; Kieback, D.G.; Markopoulos, C.; Dirix, L.; Seynaeve, C.; Boutros, P.C.; Rea, D.W.; Bartlett, J.M.S.
- Date
- 2016-02-15
- Journal
- Cancer Research
- Volume
- 76